CMR-derived LA-GLS predicted MACE in low-risk HCM patients with HR 2.17; combined with LVEF >50% and LGE <5%, identified subgroup with only 2% MACE rate.
Does CMR-derived LA-GLS predict major adverse cardiovascular events in patients with hypertrophic cardiomyopathy at low risk of sudden cardiac death?
CMR-derived LA-GLS improves risk stratification for major adverse cardiovascular events in HCM patients conventionally considered at low risk for sudden cardiac death.
Absolute Event Rate: 0% vs 0%
Abstract Aims Hypertrophic cardiomyopathy (HCM) is associated with diverse cardiovascular outcomes. While the HCM Risk-SCD score effectively stratifies sudden cardiac death (SCD) risk, it provides limited insight into global cardiovascular prognosis, particularly among low-risk patients (HCM Risk-SCD score 4%). Left atrial global longitudinal strain (LA-GLS), derived from cardiovascular magnetic resonance (CMR), may enhance risk stratification. This study aimed to assess the prognostic value of CMR-derived LA-GLS in predicting major adverse cardiovascular events (MACE) in a cohort of low-risk HCM patients. Methods and Results In this retrospective longitudinal single-centre study, 183 low-risk HCM patients underwent CMR with LA-GLS assessment via feature tracking. The primary endpoint was a composite of MACE, including ventricular arrhythmias, heart failure, thromboembolic events, or all-cause death. The mean age was 64 ± 19 years; 47% were female. Over a median follow-up of 6.1 (2.8-8.5) years, 67 patients (37%) experienced MACE. The variables associated with MACE after adjustment were LA-GLS (HR 2.17, 95% CI 1.31-3.58, p = 0.002), maximal left ventricular (LV) wall thickness (HR 1.10, 95% CI 1.02-1.18, p = 0.015), late gadolinium enhancement (LGE) 5% of total myocardial mass (HR 2.00, 95% CI 1.01-3.97 p = 0.049), and LV ejection fraction (LVEF) 50% (HR 12.86, 95% CI 5.91-33.66, p 0.001). Patients with LVEF 50%, LGE 5%, and an LA-GLS 37.6% had a MACE rate of only 2%, identifying an overall low-risk subgroup. The prognostic value of LA-GLS was validated in an external cohort of 202 low-risk HCM patients. Conclusion CMR-derived LA-GLS improves risk stratification in HCM patients at low-risk of SCD and may refine management strategies and optimise resource allocation.
Faggiano et al. (Tue,) reported a other. CMR-derived LA-GLS predicted MACE in low-risk HCM patients with HR 2.17; combined with LVEF >50% and LGE <5%, identified subgroup with only 2% MACE rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: